Table 1 Comparison of the general conditions of patients in the two groups

Gender

1.286

0.257

 Men

32 (82.1%)

98 (73.1%)

 Women

7 (17.9%)

36 (26.9%)

Age (years)

62 [58,69]

68 [60,72]

0.015*

Previous abdominal surgery

0.261

0.610

 Yes

10 (25.6%)

40 (29.9%)

 No

29 (74.4%)

94 (70.1%)

Diabetes

0.152

0.697

 Yes

2 (5.1%)

5 (3.7%)

 No

37 (94.9%)

129 (96.3%)

Hypertension

1.553

0.213

 Yes

9 (23.1%)

45 (33.6%)

 No

30 (76.9%)

89 (66.4%)

Heart disease

2.608

0.106

 Yes

4 (10.3%)

5 (3.7%)

 No

35 (89.7%)

129 (96.3%)

Smoking

0.230

0.632

 Yes

12 (30.8%)

36 (26.9%)

 No

27 (69.2%)

65 (48.5%)

Drinking

0.010

0.920

 Yes

7 (17.9%)

25 (18.7%)

 No

32 (82.1%)

109 (81.3%)

BMI (kg/m²)

22.4 (± ± .4)

23.1 (± ± .1)

0.234

CA199 (ng/mL)

10.2 [6.3, 18.7]

8.4 [5.0, 11.2]

0.096

AFP (ng/mL)

2.09 [1.5, 3.3]

1.7 [1.3, 2.8]

0.113

CEA (ng/mL)

2.7 [1.7, 4.5]

1.8 [1.3, 2.9]

0.013*

WBC count (× 10⁹/L)

7.0 [5.2, 10.5]

5.7 [4.5, 6.9]

 < 0.001*

Albumin level (g/L)

38.1 [35.2, 43.4]

42.2 [36.7, 46.2]

0.033*

Time of GC surgery (min)

180 [150, 190]

160 [132, 180]

0.021*

Intraoperative blood transfusion

0.204

0.652

 Yes

1 (2.6%)

2 (1.5%)

 No

38 (97.4%)

132 (98.5%)

Intraoperative bleeding (ml)

100 [50, 200]

200 [100, 200]

0.705

Surgical approach

1.487

0.223

 Laparoscopic

16 (41.0%)

41 (30.6%)

 Open

23 (59.0%)

93 (69.4%)

Tumor location

0.462

0.497

 Cardia/Fundus

16 (41.0%)

47 (35.1%)

 Gastric body/Pylorus

23 (59.0%)

87 (64.9%)

Tumor size (cm)

6 [5, 6]

5 [3, 6]

0.011*

Surgical procedure

0.639

0.726

 Total gastrectomy

33 (84.6%)

107 (79.9%)

 Proximal gastrectomy

1 (2.6%)

7 (5.2%)

 Distal gastrectomy

5 (12.8%)

20 (14.9%)

Reconstruction method

3.561

0.313

 Roux-en-Y

35 (89.7%)

122 (91.0%)

 Uncut Roux-en-Y

3 (7.7%)

3 (2.2%)

 Billroth-1

0 (0%)

1 (0.7%)

 Billroth-2

1 (2.6%)

8 (6.0%)

Combined organ resection

0.889

0.346

 Yes

0 (0%)

3 (2.2%)

 No

39 (100%)

131 (97.8%)

Close Petersen’s defect

0.336

0.562

 Yes

32 (82.1%)

115 (85.8%)

 No

7 (17.9%)

19 (14.2%)

Total length of stay (days)

15 [14, 19]

16 [14, 19]

0.337

Postoperative hospital stay (days)

13 [12, 13]

13 [12, 14]

0.091

Postoperative metastasis

13.218

 < 0.001*

 Yes

6 (15.4%)

2 (1.5%)

 No

33 (84.6%)

132 (98.5%)

Pathological T stage

3.407

0.333

 T1

5 (12.8%)

32 ( 23.9%)

 T2

6 (15.4%)

11 (8.2%)

 T3

5 (12.8%)

15 (11.2%)

 T4

23 (59.0%)

76 (56.7%)

Pathological N stage

1.074

0.753

 N0

15 (38.5%)

53 (39.6%)

 N1

5 (12.8%)

25 (18.7%)

 N2

8 (20.5%)

21 (15.7%)

 N3

11 (28.2%)

35 (26.1%)

Pathological TNM stage

2.368

0.306

 I

17.9 (1%)

38 (28.4%)

 II

11 (28.2%)

26 (19.4%)

 III

21 (53.8%)

70 (52.2%)

Pathological type

1.416

0.702

 Adenocarcinoma

37 (94.9%)

109 (81.3%)

 Mucinous adenocarcinoma

1 (2.6%)

2 (1.5%)

 Signet-ring cell carcinoma

1 (2.6%)

1 (4.5%)

 Neuroendocrine carcinoma

0 (5.1%)

2 (0.7%)

Invasion of nerve

5.735

0.017*

 Yes

22 (56.4%)

47 (35.1%)

 No

17 (43.6%)

87 (64.9%)

Transfer of vessel

1.581

0.209

 Yes

18 (46.2%)

47 (35.1%)

 No

21 (53.8%)

87 (64.9%)

Abdominal pain

3.419

0.064

 Yes

39 (100%)

123 (91.8%)

 No

0 (0%)

11 (8.2%)

Abdominal distension

0.072

0.788

 Yes

25 (64.1%)

89 (66.4%)

 No

14 (35.9%)

45 (33.6%)

Nausea

0.784

0.376

 Yes

26 (66.7%)

99 (73.9%)

 No

13 (33.3%)

35 (26.1%)

Vomiting

1.560

0.212

 Yes

18 (46.2%)

77 (57.5%)

 No

21 (53.8%)

57 (42.5%)

Stop farting

0.245

0.620

 Yes

25 (64.1%)

80 (59.7%)

 No

14 (35.9%)

54 (40.3%)

Cessation of bowel movements

0.040

0.841

 Yes

26 (66.7%)

87 (64.9%)

 No

13 (33.3%)

47 (35.1%)

Treatment of SBO

0.010

0.920

 Surgery

7 (17.9%)

25 (18.7%)

 Conservative

32 (82.1%)

109 (81.3%)

Fart time after treatment (days)

2 [0, 5]

2 [0, 3]

0.290

Defecation time after treatment (days)

3 [0, 5]

2 [0, 5]

0.601

The interval from gastrectomy to first SBO (months)

34 [23, 43]

9 [5, 18]

 < 0.001*